On November 8, 2022,Taysha Gene Therapies, Inc. closed the transaction. The company received $50 million in its final tranche.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 USD | -1.27% | +32.48% | +75.14% |
05-14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
05-14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,487 JPY | -1.75% | -3.50% | 17.48B | ||
3.1 USD | -1.27% | +32.48% | 587M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.14% | 587M | |
+33.17% | 50.85B | |
+0.00% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.92% | 26.11B | |
-22.01% | 19.13B | |
+8.51% | 13.05B | |
+27.68% | 12.16B | |
+24.50% | 12.08B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Taysha Gene Therapies, Inc. announced that it has received $79.99982 million in funding from Astellas Pharma Inc., Audentes Therapeutics, Inc.